在动脉样硬化心血管疾病中更新HDL
Leonie Schoch1, Sebastián Alcover2, Teresa Padró2
1Cardiovascular Program, Institut de Recerca, Hospital de la Santa Creu I Sant Pau, IIB Sant Pau, 08025 Barcelona, Spain; Faculty of Medicine, University of Barcelona (UB), 08036 Barcelona, Spain.
概括
高密度脂蛋白 (HDL) 胆固醇的使用
科学领域:
- 心血管科学 心血管科学
- 脂质代谢 脂质代谢是什么
- 动脉样硬化研究 动脉样硬化研究
背景情况:
- 流行病学研究表明,高密度胆固醇 (HDL-C) 和动脉样硬化心血管疾病 (ASCVD) 之间存在逆相关性.
- 高密度胆固醇颗粒具有除逆胆固醇运输之外的心脏保护功能.
- 针对增加HDL-C水平的临床试验产生了可疑的结果.
研究的目的:
- 审查目前对HDL在ASCVD中的作用的理解.
- 探索HDL粒子的异质性和组成.
- 讨论HDL-C升高疗法的临床结果,包括CETP抑制剂.
主要方法:
- 关于高密度胆固醇功能和组成的最新研究的文献综述.
- 关于提高HDL-C的药物的临床试验数据的分析.
- 专注于胆固醇转移蛋白 (CETP) 抑制剂.
主要成果:
- 有证据表明,HDL的保护功能取决于粒子组成,而不仅仅是胆固醇含量.
- "HDL质量超过数量"假设正在获得引力.
- 提高HDL-C的药物的临床结果,特别是CETP抑制剂,需要仔细考虑.
结论:
- 提高HDL-C的有效性需要一个细微的观点,强调颗粒质量和成分.
- 对HDL异质性的进一步研究对于开发有效的心血管疗法至关重要.
- 针对特定的HDL组件可能为ASCVD预防提供更有前途的策略.
更多相关视频
相关概念视频
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Atherosclerosis I: Introduction
9
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
9
Coronary Artery Disease IV: Preventive Measures
23
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
23
Coronary Artery Disease I: Introduction
17
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
17
Coronary Artery Disease II: Pathophysiology
12
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
12
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
674
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
674


